Cost Curve
everything drug pricing and policy, every day
Connect
Plus some updates on this week’s pharm-to-table drama, and ‘today’s lol’ becomes a recurring feature
Plus a novel argument that suggests that U.S. drug prices aren’t as high as usually assumed
And a new study says that 340B is driving up hospital costs for employers by $36 billion (!)
Plus Noom plugs into Lilly’s pharm-to-table ecosystem
And when it comes to obesity meds, we should listen to Axl: All we need is just a little patience
Plus ... how a wildly speculative NEJM piece on ‘pharm to table’ misses the point
Plus some links on tariffs and a new study that looks at 340B margins
And a new paper underscores how tough it can be to talk about launch prices
Plus a bunch of items that I missed last week on everything from a row in the UK to pricing decisions in an increasingly competitive rare disease
And retail pharmacy is in deep trouble. Could a new effort from Optum reverse the trend?
Plus a new filing from pharma companies in the latest legal battle over the IRA
And is the government getting wobbly on its objections to the 340B rebate model?
